A novel mutation in KIF5A in a Malian family with spastic paraplegia and sensory loss

Cheick O. Guinto¹, Salimata Diarra¹, Salimata Diallo², Lassana Cissé¹, Thomas Coulibaly¹, Seybou H. Diallo², Abdoulaye Tamégá¹, Ke-Lian Chen³, Alice B. Schindler³, Koumba Bagayoko¹, Assiatou Simaga⁴, Craig Blackstone³, Kenneth H. Fischbeck³ & Guida Landouré¹,³

¹Service de Neurologie, Centre Hospitalier Universitaire du Point “G”, Bamako, Mali
²Service de Neurologie, Centre Hospitalier Universitaire de Gabriel Touré, Bamako, Mali
³Neurogenetics Branch, NINDS, National Institutes of Health, Bethesda, Maryland
⁴Institut d’Ophtalmologie Tropicale de l’Afrique, Bamako, Mali

Abstract

Hereditary spastic paraplegias (HSPs) are well-characterized disorders but rarely reported in Africa. We evaluated a Malian family in which three individuals had HSP and distal muscle atrophy and sensory loss. HSP panel testing identified a novel heterozygous missense mutation in KIF5A (c.1086G>C, p.Lys362Asn) that segregated with the disease (SPG10). Lys362 is highly conserved across species and Lys362Asn is predicted to be damaging. This study shows that HSPs are present in sub-Saharan Africa, although likely underdiagnosed. Increasing efficiency and decreasing costs of DNA sequencing will make it more feasible to diagnose HSPs in developing countries.

Introduction

Hereditary spastic paraplegias (HSPs) are clinically and genetically heterogeneous neurologic disorders that manifest with progressive lower extremity hypertonia and hyperreflexia along with typically more mild lower limb weakness in “pure” forms and with other associated neurologic or non-neurologic symptoms in “complicated” (or “complex”) forms.¹ HSP is often due to a progressive, length-dependent degeneration of the corticospinal tracts and posterior columns of the spinal cord, though abnormal development may play a role as well. All modes of inheritance are seen, and the clinical presentations can show striking inter- and intra-family variability. While dominant HSPs are prevalent in northern Europe and North America, recessive cases are mostly seen in North Africa, the Middle East, and Mediterranean regions.¹–³ Although prevalent in other populations, genetically confirmed HSP cases in sub-Saharan Africa in general, and West Africa in particular, are rare.⁴ Here, we report here a novel mutation in an HSP gene in a previously unstudied population in Mali.

Methods

All patients were evaluated by a group of neurologists after giving informed consent. Brain MRI plus HTLV-1 and HIV serologies were performed to exclude common causes of spasticity in this population. Nerve conduction studies (NCS) and ophthalmologic examinations were performed to assess peripheral nerve or ocular involvement. DNA was extracted from peripheral blood in all patients and subjected to genetic analysis.
available family members for genetic analysis. Next-generation DNA sequencing assessing 58 HSP genes was performed commercially (Medical Neurogenetics, Atlanta, GA). DNA from all available family members was sequenced for segregation analyses.

Results

The index subject, of Khasonka ethnicity, was admitted for an ischemic stroke of the right superficial Sylvian artery that caused weakness in his left limbs. During examination, upper motor neuron signs were noticed on the right side as well. Further investigation revealed that he had experienced problems with walking at around 20 years of age, and two of his sons had the same symptoms. Other family members were subsequently evaluated. The disease distribution within the family was consistent with autosomal dominant inheritance (Fig. 1).

Three subjects were found to be affected based on clinical examination, with spastic gait, extensor plantar responses, and brisk reflexes in all those affected (Table 1). There were no visual or hearing complaints, but the eldest patient had dysarthria, possibly due to his concurrent stroke. In addition, patients had muscle atrophy and weakness in lower extremities along with decreased pin-prick and vibration sense. NCS showed slightly decreased conduction velocities in both tibial nerves at 39 m/sec with increased F-wave latency at 63.5 msec in the 23-year-old patient (shown in italic in Table 1). The youngest patient also had an increased F-wave latency, SPG4 deletion and duplication testing was negative, and targeted HSP next-generation sequencing of one affected individual identified a heterozygous missense variant in the KIF5A gene at position c.1086G>C (Fig. 2A and B), leading to the amino acid change p.Lys362Asn. The Lys362 residue is located in a highly conserved, Lys-rich domain of the protein (Fig. 2C), and mutation in the neighboring Ala361 residue has been reported in autosomal dominant “pure” SPG10.

The p.Lys362Asn substitution of a positively charged with an uncharged amino acid is predicted to be damaging by an in silico method (Mutation Taster). Sequencing of DNA from eight other family members demonstrated that the Lys362Asn mutation co-segregates perfectly with disease status, and this variant was not seen in various SNP databases (ExAC Browser: 0.00000, dbSNP, 1000genome). Another branch of the family (individual II.4 and relatives) had a genetically confirmed spinocerebellar ataxia (SCA2) characterized by ataxia and slurred speech.

Discussion

More than 90 HSP-related genes (SPG1-78, plus others) have been reported worldwide, and mutations in about 60 identified genes have been associated with these clinical variants. However, reports of genetically confirmed HSPs in the African population are scant and involve a limited number of these genes, mostly recessive forms. In Africa, a majority of spinal disorders appears due to injury or other known causes such as infectious or tumor, but genetic forms are likely underdiagnosed because of the cost and limited availability of genetic testing. Mutations in KIF5A have been associated with both HSP (SPG10) and CMT2. Previous reports of autosomal dominant HSP caused by KIF5A mutations have shown a clinical variability within and between families, but complicated cases are more frequent, especially in some populations. In addition to spasticity, some patients have peripheral neuropathy manifesting with muscle atrophy and weakness, and sensory loss in extremities. Furthermore, a small number of cases are characterized by infantile onset with myoclonus, hypotonia, optic nerve abnormalities, dysphagia, and apnea. To our knowledge, mutation in KIF5A has not been previously reported in Africa.

In the family we describe here, the age of onset ranged from about 14–40 years, with a wide range of clinical variability. KIF5A encodes a member of the kinesin family

![Figure 1. Pedigree of the family showing the autosomal dominant inheritance pattern. Individuals with Hereditary spastic paraplegias (HSP) phenotype (solid black) and individuals with SCA (solid gray) are indicated. The arrow identifies the proband. Ages at examination are shown at the top of each symbol, and asterisks (*) identify those seen in clinic.](image-url)
of proteins that has three structural domains. The mutated residue described here is located in the coiled coil domain and is conserved across species from mammals to fruit flies. Although dominant HSPs are the most prevalent HSPs worldwide, in Africa (and in North Africa in particular where most HSP cases have been reported), recessive cases predominate. This is likely due to the high rate of consanguinity in these populations. KIF5A mutations have been reported in Asia, Europe and North America, but no cases have been reported in Africa, probably due to much more limited access to genetic testing.

In summary, our study has identified a novel, autosomal dominant missense mutation in the KIF5A gene in a Malian family, broadening the genetic heterogeneity of HSPs in the African population and expanding the geographic spectrum of SPG10. Larger cohort studies in Africa will likely uncover many new HSP cases, representing new genes as well as known genes with mutations described in other populations.

**Table 1. Phenotypic characteristics of subjects with SPG10.**

| Patient | Clinical and demographic features | Nerve conduction studies |
|---------|----------------------------------|--------------------------|
| Ill.3   | 68 M                             | Distal leg weakness, walking difficulty, sensory loss | Sensory SNAP, normal (left: sural, right: peroneal); motor CMAP, normal (left: tibial); non-invasive F wave; normal |
| IV.9    | 23 M                             | 10 Walking difficulty, sensory loss | Sensory SNAP, normal (left: sural, right: peroneal); motor CMAP, normal (left: tibial); non-invasive F wave; normal |
| IV.10   | 21 M                             | 11 Walking difficulty, sensory loss | Sensory SNAP, normal (left: sural, right: peroneal); motor CMAP, normal (left: tibial); non-invasive F wave; normal |

Figure 2. Electrophorograms of the novel KIF5A sequence variant. Sanger DNA sequencing shows an unaffected family member to be homozygous (G/G; panel A), while the affected individual is heterozygous (G/C), for the pathogenic variant (denoted by *; panel B). Protein sequence alignment of KIF5A in various species (amino acid numbers refer to the human sequence). The SPG10 mutation causes an amino acid change at Lys362, a highly conserved residue (in red, asterisk above, panel C).
Acknowledgment

This work is supported by grant number U01HG007044 administered by the National Human Genome Research Institute as part of the NIH Common Fund H3Africa Initiative and the Intramural Research Program of the NINDS, NIH.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Harding AE. Hereditary spastic paraplegias. Semin Neurol 1993;13:333–336.
2. Erichsen AK, Koht J, Stray-Pedersen A, et al. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain 2009;132:1577–1588.
3. Silva MC, Coutinho P, Pinheiro CD, et al. Hereditary ataxias and spastic paraplegias: methodological aspects of a prevalence study in Portugal. J Clin Epidemiol 1997;50:1377–1384.
4. Landouré G, Zhu P-P, Lourenço CM, et al. Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation in C19orf12. Hum Mutat 2013;34:1357–1360.
5. de Souza PVS, de Rezende Pinto WBV, de Rezende Batistella GN, et al. Hereditary spastic paraplegia: clinical and genetic hallmarks. Cerebellum 2017;16(2):525–551. In press. DOI 10.1007/s12311-016-0803-z
6. Boukhris A, Stevanin G, Feki I, et al. Tunisian hereditary spastic paraplegias: clinical variability supported by genetic heterogeneity. Clin Genet 2009;75:527–536.
7. Roman GC. Tropical myelopathies. Handb Clin Neurol 2014;121:1521–1548.
8. Liu YT, Laura M, Hershenson J, et al. Extended phenotypic spectrum of KIF5A mutations: From spastic paraplegia to axonal neuropathy. Neurology 2014;83:612–619.
9. Goizet C, Boukhris A, Mundwiller E, et al. Complicated forms of autosomal dominant hereditary spastic paraplegia are frequent in SPG10. Hum Mutat 2009;30: E376–E385.
10. Duis J, Dean S, Applegate C, et al. KIF5A mutations cause an infantile onset phenotype including severe myoclonus with evidence of mitochondrial dysfunction. Ann Neurol 2016;80:633–637.
11. Wang L, Brown A. A hereditary spastic paraplegia mutation in kinesin-1A/KIF5A disrupts neurofilament transport. Mol Neurodegener 2010;5:52.
12. Reid E, Kloos M, Ashley-Koch A, et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 2002;71:1189–1194.
13. Rinaldi F, Bassi MT, Todeschini A, et al. A novel mutation in motor domain of KIF5A associated with an HSP/axonal neuropathy phenotype. J Clin Neuromusc Dis 2015;16:153–158.
14. Takiyama Y. Japan Spastic Paraplegia Research Consortium (JASPAC). Brain Nerve 2014;66:1210–1217.